Aviptadil is a life-saving drug that gives hope to thousands of critically ill COVID-19 patients.
It is available for use right now, but unfortunately, many doctors and hospitals are not aware of it.
​
To get Aviptadil for your patients or loved ones, visit NeuroRX website.
RLF-100, which is a patented formulation of Aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), has been granted:
  • FDA Fast Track Designation
  • FDA emergency use Investigative New Drug authorization
  • Expanded access protocol
​and is awaiting Emergency Use Authorization and full FDA approval

Click articles below for more information:

Miracle recovery by Aviptadil as posted on Facebook
YouTube discussion between Dr. Yogendra and NeuroRX CEO Dr. Jonathan Javitt. Specifically discussing summary results of preliminary data from Phase 2b/3 clinical trial
NeuroRX CEO Dr. Jonathan Javitt discusses Aviptadil begining at 21 minutes 40 seconds
CNBC article on company that owns patent on Aviptadil
Nebraska Governor acknowledges the effectiveness of Aviptadil
Interesting overview of the uses of Vasoactive Intestinal Peptide (VIP) in the body
Yet another Nebraska man's life saved by Aviptadil
Miami doctor recovers from severe COVID-19 after treatment with Aviptadil
In depth article on success of Aviptadil for patient in North Platte, Nebraska (different from article/video below)
European Biotechnology article on Aviptadil
Relief Therapeutics announces successful results from Expanded Access Protocol (EAP)
Video: Houston Methodist Hospital sees encouraging results of Aviptadil study
Israel to conduct Aviptadil study
University of Miami Hospital participating in Aviptadil clinical trial
Article: Nebraska man successfully treated with Aviptadil
Video: Nebraska man successfully treated with Aviptadil
Relief Therapeutics announces enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 patients
Interim results published to ResearchGate
​​Relief Therapeutics announces: Trial is on track for treatment of COVID-19 respiratory failure
Aviptadil is associated with a 9-fold increased probability of survival and recovery from COVID-19 respiratory failure
Rapid recovery seen in patients on ventilators and extracorporeal membrane oxygenation (ECMO)
NeuroRx requests Emergency Use Authorization for RLF-100™ (Aviptadil) in the treatment of patients with critical COVID-19​
FDA grants Investigational New Drug (IND) status for inhaled use of RLF-100 (Aviptadil) to treat patients with COVID-19
Help spread the word

​Follow us, and share, on Facebook
so the world can learn
​about Aviptadil.

Want to help us spread the word about this life saving drug? Contact us here for details:
contribute2socialmedia@aviptadilsaveslives.com
Disclaimer: this website is not supported or authorized by Relief Therapeutics or NeuroRX.